Table 1

Baseline demographics and clinical characteristics for the total population and for ASDAS inactive to moderate disease activity (<2.1) and high disease activity (≥2.1) at 24 weeks of follow-up (last observation carried forward)*

Total patient population†Inactive to moderate disease activityHigh disease activityp Value
n=162n=84n=67
Demographics
 Age, years43±1140±1144±11NS
 Men (%)115 (71)64 (76.2)42 (64.2)NS
 BMI25.7 (23.4–29.7)24.7 (23.1–27.8)27.7 (24.4–31)0.001
Disease status
 Disease duration, years8 (3–15)9 (4–17)6.5 (1–15)NS
 HLA-B27 positive, n (%)118 (72.8)67 (79.8)44 (65.7)0.02
 CRP (mg/L)12 (3–27)13 (3–27)11 (3–21)NS
 ESR (mm/h)22 (6–38)21 (5–37)22 (6–40)NS
 ASDAS CRP3.6±0.93.5±0.93.8±0.9NS
 BASDAI6.1 (5.1–7.1)5.7 (4.6–6.8)6.6 (5.5–7.6)0.03
 GDA VAS7 (4–8)6 (3–8)7 (4–8)NS
 BASFI5.9±2.35.2±2.46.6±1.9<0.001
DMARD therapy
 Prior biologicals, n (%)10 (6.2)3 (3.6)7 (10.4)NS
 Methotrexate use, n (%)4 (2.5)4 (4.8)0 (0)NS
 Sulfasalazine use, n (%)16 (9.9)11 (13.1)5 (7.5)NS
 NSAID use, n (%)114 (70.4)65 (77.4)45 (67.2)NS
  • *Mean values±SD, median (IQR) or numbers (percentages) are shown.

  • †Of 11 patients ASDAS at 24 weeks of treatment could not be calculated because baseline ASDAS was missing (n=8) or only baseline ASDAS was available (n=3).

  • ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GDA VAS, general disease activity on a visual analogue scale (0–10); HLA-B27, human leukocyte antigen B27; NSAID, non-steroid anti-inflammatory drug.